Epidemiological and clinical studies have demonstrated that dietary supplementation of
selenium (Se) could reduce the incidence of human
cancers. In this study,
selenocystine, a nutritionally available selenoamino
acid, was identified as a novel agent with broad-spectrum antitumor activity. A panel of eight human
cancer cell lines was shown to be susceptible to
selenocystine, with IC(50) values ranging from 3.6 to 37.0 microM.
Selenocystine induced dose-dependent apoptosis in A375, HepG2 and MCF7 cells was evaluated by flow cytometric analysis and
annexin-V staining assay. Mechanistic studies showed time- and dose-dependent increases in intracellular
reactive oxygen species (ROS) in susceptible
cancer cells (MCF7 and HepG2 cells) treated with
selenocystine. However,
selenocystine-induced ROS overproduction was not observed in non-susceptible normal human fibroblast Hs68 cells. Significant
DNA strand breaks were observed in
selenocystine-treated MCF7 and HepG2 cells as examined by single-cell gel electrophoresis (Comet assay). The
thiol-reducing
antioxidants,
glutathione and
N-acetylcysteine, inhibited intracellular ROS generation,
DNA strand breaks and accumulation of sub-G1 population in MCF7 cells exposed to
selenocystine. Our results suggest a possible role of ROS as a mediator of the signaling pathway of
selenocystine-induced, DNA damage-mediated apoptosis in susceptible
cancer cells.